VERAXA Biotech Launches on Nasdaq to Develop Cancer Therapies

Updated at: June 11, 2026 at 01:05 PM

On June 11, 2026, Zurich-based biopharmaceutical company VERAXA Biotech AG officially reached a major milestone by launching on the Nasdaq Capital Market.

nounJune 11, 2026

nounVERAXA Biotech AG

nounNasdaq Capital Market

Following this merger, the firm now trades under the ticker symbol 'VRXA.'

nounmerger

VERAXA specializes in developing advanced cancer therapies, specifically utilizing its proprietary BiTAC platform.

verbdevelop

nouncancer

This technology aims to create 'AND-gated' treatments that specifically identify and attack cancer cells while leaving healthy tissue unharmed.

nouncancer

As Chairman Oliver R.

nounchairman

Baumann noted, this Nasdaq listing is a pivotal step in scaling their innovative technology and bringing next-generation cancer solutions to patients globally.

adjectiveinnovative

nouncancer

🎉

End of article

You read 6 focus sentences.

Challenge Mode

Comprehension Questions

On what date did VERAXA Biotech AG become a publicly traded company on Nasdaq?

June 11, 2025

June 11, 2026

June 11, 2027

Reveal Answer

✓

Correct Choice

June 11, 2026

What is the primary function of VERAXA's proprietary BiTAC platform?

To create conditionally activated therapies that target cancer cells while sparing healthy tissue

To develop new gene-editing tools for hereditary diseases

To provide diagnostic screening for heart conditions

Reveal Answer

✓

Correct Choice

To create conditionally activated therapies that target cancer cells while sparing healthy tissue

How did VERAXA Biotech AG enter the public stock market?

By completing a business combination with Voyager Acquisition Corp.

By merging with a pharmaceutical retail chain

Through an initial public offering on the London Stock Exchange

Reveal Answer

✓

Correct Choice

By completing a business combination with Voyager Acquisition Corp.

What is the ticker symbol for VERAXA Biotech AG common stock on the Nasdaq?

VRXA

VRXAW

VXB

Reveal Answer

✓

Correct Choice

VRXA

What is the primary goal for the $77.5 million raised by VERAXA?

To accelerate the development of oncology drug candidates and clinical programs

To acquire a larger competitor in the Zurich area

To pivot the company toward general healthcare software

Reveal Answer

✓

Correct Choice

To accelerate the development of oncology drug candidates and clinical programs

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play